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STAT3 (signal transducers and activators of 
transcription 3) is a transcription factor in the JAK/STAT 
signaling pathway in response to extracellular cytokines 
and growth factors [1]. STAT3 is constitutively activated 
in human malignancies and has been shown to play an 
important role in many facets of human cancers including 
oncogenesis, angiogenesis, metastasis, immune evasion, 
and EMT [2]. Thus, STAT3 has been a sought-after target 
for drug discovery. Although many STAT3 inhibitors have 
been identified and studied over the last decade including 
peptidomimetics and small molecule compounds [3], 
most of them target the SH2 domain, inhibiting activation 
and dimerization of STAT3 (Figure 1). This approach 
has yet to result in an FDA-approved STAT3-targeting 
therapeutics. Recently, STAT3-selective small molecule 
inhibitors targeting the DNA-binding domain (DBD) of 
STAT3 were identified that effectively inhibited growth 
and metastasis of xenograft tumors [4, 5], which may have 
the potential to be further developed as cancer therapeutics 
targeting STAT3. 
DBDs of transcription factors and DNA damage 
repair proteins are generally considered “undruggable” 
with flat and similar surface areas [6, 7], which may not 
allow appropriate and selective inhibitor binding. Thus, 
these domains and sometimes the entire proteins are 
avoided as targets for drug discovery. In a recent study 
[4], Huang et al. challenged this prevailing taboo by 
developing an improved in-silico screening approach 
to eliminate potential non-selective inhibitors, in which 
top-scoring compounds targeting the DBD of STAT3 off 
the in-silico screening of a ChemDiv chemical library 
were docked onto the DBD of STAT1. Any compounds 
that were predicted to also bind to the DBD of STAT1 
were eliminated due to potential lack of selectivity. This 
improved approach helped the authors identify a STAT3-
selective hit molecule, inS3-54, which inhibited cancer 
cell proliferation with an IC50 of 3.2-5.4 µM in multiple 
cancer cell lines by inhibiting STAT3-dependent gene 
expression and inducing apoptosis [4]. However, inS3-
54 had poor pharmacokinetics and was not absorbed in 
animal studies. 
Editorial
Figure 1: Schematic representation of JAK/STAT3 signaling pathway and direct inhibition of STAT3 activation by 
SH2 inhibitors and DNA-binding activity by DBD inhibitors. CK, cytokine; JAK, Janus kinase; DBD, DNA-binding domain.
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To improve the pharmacokinetic properties of inS3-
54, Huang et al. [5] analyzed 69 analogues of inS3-54 
and identified three analogues that were more effective 
than inS3-54 with IC50 of 1.8-5.3 µM against multiple 
cancer cell lines. These active analogues were not only 
selective to STAT3 over STAT1 as demonstrated using 
electrophoretic mobility shift assay, they had no effect on 
the survival of STAT3-null hematopoietic progenitor cells, 
suggesting that they are likely specific to STAT3. One of 
the effective analogues, inS3-54A18, was selected as a 
lead compound because it was soluble in a proprietary oral 
formulation suitable for in-vivo study and demonstrated 
to not only effectively inhibit cancer cell survival, but also 
inhibited migration and invasion of cancer cells, the in-
situ DNA-binding activity of STAT3, and the growth and 
metastasis of xenograft tumors in vivo with repeated oral 
dosing.
Huang et al. also conducted structure-activity 
relationship analysis of all analogues [5], which revealed 
a pharmacophore, 5-phenyl-1H-pyrrol-2(3H)-ketone 
core structure with different functional groups (Figure1). 
Compounds with R1 being p-hydroxybenzene or 
p-carboxybenzene had high while compounds with R1 
being m-hydroxybenzene or m-carboxybenzene had low 
or no STAT3-inhibitory activity. The active compounds 
also appeared to have nitrobenzene, p-chlorobenzene, or 
benzenamine while inactive ones had p-methoxylbenzene 
as R2 group [5].
Although many inhibitors targeting the SH2 domain 
of STAT3 have previously been reported, most of these 
studies provided no direct evidence that these inhibitors 
indeed bind to the intended targeting site. In contrast, 
direct and specific binding to the DBD of STAT3 by the 
DBD-targeting inhibitors was validated by Huang et al [5] 
using immobilized compounds and purified recombinant 
STAT3 proteins of various domains in a pulldown assay. 
These findings on inhibitors targeting the DBD of 
STAT3 by Huang et al. [4, 5] not only provide potential 
candidates for novel anticancer drug development targeting 
STAT3, but also suggest that DBDs of transcription factors 
can be exploited as targeting sites for drug discovery and 
that the prevailing “undruggable” DBD of transcription 
factors may be druggable. Thus, targeting the DBD of 
oncogenic transcription factors may lead to identification 
of novel inhibitors that can be developed into a new class 
of therapeutics.
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